What is X4 Pharmaceuticals's market cap?

X4 Pharmaceuticals (XFOR) has a market capitalization of $371.6M and trades on NASDAQ.

Who are X4 Pharmaceuticals's competitors?

X4 Pharmaceuticals's key competitors include Amgen Inc., Bristol-Myers Squibb, Fulcrum Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does X4 Pharmaceuticals partner with?

X4 Pharmaceuticals's notable partners include Norgine Pharma UK Ltd., Abbisko Therapeutics Co. Ltd., Genzyme Corporation, and others.

Where is X4 Pharmaceuticals headquartered?

X4 Pharmaceuticals is headquartered in United States of America and employs approximately 93 people. It has been publicly traded since 2017.

X4 Pharmaceuticals

XFOR

X4 Pharmaceuticals is a late-stage biopharmaceutical company dedicated to developing and commercializing novel oral therapeutics for rare hematological diseases.

Market cap

$371.62M+2,825%

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$2.5MMiss by $731.0K EPS-$0.16Beat by $0.04

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$2.4M

EPS estimate-$0.19

Competitors

By market cap

Johnson & Johnson$640.91B+60.1%

Amgen$203.07B+25.3%

Bristol-Myers Squibb$127.75B+32.1%

Rhythm Pharmaceuticals, Inc.$7.3B+28.8%

Zevra Therapeutics, Inc.$574.0M-2.9%

X4 Pharmaceuticals$371.6M+2,330%

Fulcrum Therapeutics, Inc.$248.5M-41.0%

Karyopharm Therapeutics$160.7M+326%

By revenue growth

Zevra Therapeutics, Inc.+201%

Rhythm Pharmaceuticals, Inc.+58.7%

Amgen+9.1%

Johnson & Johnson+8.1%

Bristol-Myers Squibb+1.8%

By net margin

Zevra Therapeutics, Inc.101.58%+328pp

Johnson & Johnson21.48%-3.5pp

Amgen20.96%+3.6pp

Bristol-Myers Squibb15.01%+3.8pp

Rhythm Pharmaceuticals, Inc.-93.33%+29.9pp

Profile

X4 Pharmaceuticals is a late-stage biopharmaceutical company dedicated to developing and commercializing novel oral therapeutics for rare hematological diseases. The company's primary value proposition centers on targeting the CXCR4/CXCL12 pathway to mobilize mature white blood cells from the bone marrow into the bloodstream. Its lead asset is an oral small-molecule antagonist designed to address significant unmet needs in primary immunodeficiencies and chronic neutropenic disorders.

Competitive position

X4 is a first-mover in oral CXCR4 antagonism for WHIM syndrome with a commercially approved product, currently seeking to expand into the larger chronic neutropenia market.

GeographiesUnited States, European Union, United Kingdom, China, Middle East, North Africa

Customer segmentsRare disease patients, Hematologists, Oncologists

Business modelR&D-driven drug development, Commercial-stage pharmaceutical sales, Licensing and royalties

SuppliersContract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Raw material suppliers, Intellectual property licensors

CustomersSpecialty pharmacies, International pharmaceutical distributors, Healthcare institutions, Patients with rare hematology diseases

CountryUnited States of America

Listed2017

Employees93.0

CEOAdam R. Craig

SectorHealthcare

IndustryBiotechnology

Websitex4pharma.com

FilingsSEC EDGAR

Questions, answered.

What is X4 Pharmaceuticals's market cap?: X4 Pharmaceuticals (XFOR) has a market capitalization of $371.6M and trades on NASDAQ.
Who are X4 Pharmaceuticals's competitors?: X4 Pharmaceuticals's key competitors include Amgen Inc., Bristol-Myers Squibb, Fulcrum Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does X4 Pharmaceuticals partner with?: X4 Pharmaceuticals's notable partners include Norgine Pharma UK Ltd., Abbisko Therapeutics Co. Ltd., Genzyme Corporation, and others.
Where is X4 Pharmaceuticals headquartered?: X4 Pharmaceuticals is headquartered in United States of America and employs approximately 93 people. It has been publicly traded since 2017.